Moreover, targeting IL‐10 or CXCR4 alongside CAR T‐cell therapy enhanced cytotoxicity in CLL, suggesting a promising strategy to overcome treatment resistance. The gene discussed is IL10; the disease is B-cell chronic lymphocytic leukemia.